Colonoscopy screening is proven to reduce mortality rates for colorectal cancer, which relies on early detection and removal of colonic polyps. AmplifEYE is a FDA-approved device with a row of flexible detection arms attached to the tip of colonoscope which can separate colonic folds during scope withdrawal and is believed to improve polyp detection. Real-life clinical data on this relatively new device is lacking and this study aims to compare the adenoma and polyp detection rates in AmplifEYE-assisted colonoscopy versus standard colonoscopy.
This is a prospective, randomized controlled study. Patients admitted to Queen Elizabeth Hospital and Our Lady of Maryknoll Hospital for colonoscopy are randomly allocated 1:1 to receive either colonoscopy equipped with AmplifEYE (AC) or standard colonoscopy (SC). All study team members will have a prior run-in phase of performing at least 5 AmplifEYE colonoscopies before starting the study. The colonic polyp detection rate (PDR), adenoma detection rate (ADR), serrated polyp detection rate (SDR), caecal intubation time, colonoscope withdrawal time, procedure pain and any adverse events were analyzed in each group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
355
AmplifEYE colonoscopy
Department of Medicine, Queen Elizabeth Hospital
Hong Kong, Hong Kong
Adenoma detection rate
number of patients in whom at least one adenoma could be found
Time frame: 1 day
Polyp detection rate
number of patients in whom at least one polyp could be found
Time frame: 1 day
Serrated polyp detection rate
number of patients in whom at least one serrated polyp could be found
Time frame: 1 day
caecal intubation rate
number of patients in whom caecal intubation is acheived
Time frame: 1 day
caecal intubation time
time beginning with the insertion of the colonoscope until reaching the caecum
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.